News | February 23, 2022
Vicore advances on new chemical entity from VP03 program
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
Prior to joining Biosion, Edwards was Vice President of Corporate Strategy and operations at Ionis Pharmaceuticals.
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS HF System, a small implantable sensor that can flag early warning signs of worsening heart failure
The facility will manufacture its Herceptin biosimilar, Tuznue
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
The investment in Indian clinical technology expertise in Hyderabad comes amid the clinical trials sector's move towards decentralised trials
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
Subscribe To Our Newsletter & Stay Updated
